Stock Scorecard



Stock Summary for Atossa Therapeutics Inc (ATOS) - $2.45 as of 10/7/2026 1:58:57 PM EST

Total Score

10 out of 30

Safety Score

25 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for ATOS

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for ATOS

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for ATOS

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for ATOS

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for ATOS (25 out of 100)

Stock Price Rating (Max of 10) 3
Historical Stock Price Rating (Max of 10) 4
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 3
Book Value to Price (Max of 10) 6
Analyst Buy Ratings (Max of 5) 2
Analyst Strong Buy Ratings (Max of 5) 3
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 3
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for ATOS

Atossa Therapeutics, Inc. (ATOS) Stock Price, News, Quote & History 10/2/2026 4:29:00 AM
Enterprise value to EBITDA forward of Atossa Therapeutics, Inc. – HAN:YAG 9/30/2026 7:57:00 PM
Atossa plans shareholder stake in potential PRV proceeds 9/30/2026 5:32:00 PM
Atossa Therapeutics, Inc. (ATOS) Plans CVR Paying Up To $50M From Potential PRV 9/30/2026 9:30:00 AM
Atossa Therapeutics Announces Plan to Issue Stapled CVR for Shareholders Tied to Potential Rare Pediatric Disease Priority Review Voucher 9/29/2026 7:57:00 PM
Atossa Therapeutics, Inc. Revenue Breakdown – HAN:YAG 9/29/2026 7:57:00 PM
Atossa Plans $50M-Capped CVR for Voucher Proceeds | ATOS Stock News 9/29/2026 7:57:00 PM
Atossa plans CVR issuance tied to priority review voucher 9/29/2026 12:59:00 PM
Atossa CEO to join Harvard panel on aging disease drug development and regulatory strategies 9/25/2026 1:50:00 AM
Atossa Therapeutics CEO Dr. Steven Quay to Participate in ARDD 2026 Panel on Clinical Trials and Regulatory Pathways for Diseases of Aging 9/24/2026 7:57:00 PM

Financial Details for ATOS

Company Overview

Ticker ATOS
Company Name Atossa Therapeutics Inc
Country USA
Description Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops drugs in the areas of oncology and infectious diseases. The company is headquartered in Seattle, Washington.
Sector Name HEALTHCARE
Industry Name BIOTECHNOLOGY
Most Recent Quarter 6/30/2026
Next Earnings Date 11/11/2026

Stock Price History

Last Day Price 2.45
Price 4 Years Ago 7.93
Last Day Price Updated 10/7/2026 1:58:57 PM EST
Last Day Volume 54,625
Average Daily Volume 57,271
52-Week High 19.35
52-Week Low 1.70
Last Price to 52 Week Low 44.12%

Valuation Measures

Trailing PE N/A
Industry PE 38.21
Sector PE 44.87
5-Year Average PE -3.53
Free Cash Flow Ratio 0.94
Industry Free Cash Flow Ratio 16.63
Sector Free Cash Flow Ratio 35.39
Current Ratio Most Recent Quarter 5.69
Total Cash Per Share 2.61
Book Value Per Share Most Recent Quarter 2.69
Price to Book Ratio 0.82
Industry Price to Book Ratio 11.59
Sector Price to Book Ratio 26.31
Price to Sales Ratio Twelve Trailing Months 1,872.06
Industry Price to Sales Ratio Twelve Trailing Months 22.65
Sector Price to Sales Ratio Twelve Trailing Months 28.44
Analyst Buy Ratings 1
Analyst Strong Buy Ratings 1

Share Statistics

Total Shares Outstanding 9,979,300
Market Capitalization 24,449,285
Institutional Ownership 13.61%

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -36.33%
Reported EPS 12 Trailing Months -4.45
Reported EPS Past Year -2.06
Reported EPS Prior Year -4.19
Net Income Twelve Trailing Months -37,709,000
Net Income Past Year -34,770,000
Net Income Prior Year -25,504,000
Quarterly Revenue Growth YOY 0.00%
5-Year Revenue Growth 0.00%
Operating Margin Twelve Trailing Months 0.00%

Balance Sheet

Total Cash Most Recent Quarter 26,094,000
Total Cash Past Year 41,299,000
Total Cash Prior Year 71,084,000
Net Cash Position Most Recent Quarter 26,094,000
Net Cash Position Past Year 41,299,000
Long Term Debt Past Year 0
Long Term Debt Prior Year 0
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 39,353,000
Total Stockholder Equity Prior Year 71,477,000
Total Stockholder Equity Most Recent Quarter 26,830,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -35,783,000
Free Cash Flow Per Share Twelve Trailing Months -3.59
Free Cash Flow Past Year -29,785,000
Free Cash Flow Prior Year -21,049,000

Options

Put/Call Ratio 0.00
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -0.16
MACD Signal -0.19
20-Day Bollinger Lower Band 0.81
20-Day Bollinger Middle Band 3.84
20-Day Bollinger Upper Band 6.88
Beta 1.27
RSI 32.73
50-Day SMA 0.00
150-Day SMA 0.00
200-Day SMA 0.00

System

Modified 10/6/2026 5:54:57 PM EST